Hikma Pharmaceuticals Share Discussion Threads

[jeffcranbounre] 05/1/2015 15:42

Hikma is mentioned in today's (05/01/15) ADVFN podcast.

To listen to the podcast click here>


In today's podcast:

- Nicola Duke technical analyst dicusses Quindell, Sainsburys, TERN and BP. Nicola on Twitter is @NicTrades

- And the micro and macro news including:

Quindell #QPP
Tesco #TSCO
Lloyds #LLOY
TERN #TERN
Asda
Gulf Keystone Petroleum #GKP
BP #BP.
Rockhopper Exploration #RKH
Galliford Try #GFRD
Xaar #XAR
PureCircle #PURE
Hikma Pharmaceuticals #HIK
AstraZeneca #AZN
GlaxoSmithKline #GSK
Marks & Spencer #MKS
Sainsbury #SBRY

Every Tuesday is Ten Bagger Tuesday on the podcast. If you know of a stock, whose share price has the potential to increase ten fold, just click the link below.



(All it involves is filling out a form that will take you around 5 minutes and you don't personally appear on the podcast).

Once a week, on a Friday, I feature a tip from a listener to this podcast, if you'd like to suggest a stock click the link below:



(Again all it involves is filling out a form that will take you around 5 minutes and you don't personally appear on the podcast).

You can subscribe to this podcast in iTunes by clicking

To follow me on Twitter click

As a listener to the ADVFN podcast you can take advantage of some exclusive first year discounts on popular subscriptions:

Bronze - £50 (normally £73.82/year)
Silver - £145 (normally £173.71/year)
Level 2 - £350 (normally £472.94/year)

Call 0207 0700 961 and ask for the ADVFN Podcast discount to take advantage of these reduced rates or just for more information.

Please DO NOT buy any stock recommended in this podcast basely solely on what you hear. The opinions in this podcasts are just that, opinions. Please do you own research before investing.

Justin

 

 

[broadwood] 05/1/2015 08:54

Upgraded by Jeffries.

New TP 2325.

[coppertrader] 05/12/2014 22:46

FLASH: Panmure Gordon stays hold on Hikma, target raised to 2,120p from 1,800p4 December 2014 | 12:23pmStockMarketWire.com -- See more at:

[coppertrader] 02/12/2014 17:10

Too true, hikma seems to be under the radar of many despite rising steadily for many years. As of last friday they were placed 98th on a market cap of 3893m. They only need to get their market cap to above morrisons current market cap of 4168m to be in 89th place and get automatic entry. About 7% rise from their current position.

[broadwood] 02/12/2014 14:12

Hikma Pharmaceuticals

Hikma Pharmaceuticals was founded in 1978, and floated on the London stock exchange in 2005 with a market capitalisation of £480m. In less than 10 years, Hikma has grown into a £3.9bn company and is now poised just below the threshold for entry into the FTSE 100.

Hikma operates through three businesses (branded, generics and injectables) and is a market leader in the Middle East and North Africa (MENA) region. Hikma trades on a deserved premium P/E of 22 at a share price of 1,964p, and has the financial resources to make strategic acquisitions and investments that could rapidly lift the company into the FTSE 100.

Hikma’s strong position in the MENA region also makes the company attractive to US and European drugs players. A bid (or rumours of one) could be another catalyst for catapulting Hikma’s valuation through the FTSE 100 entry level.

[broadwood] 06/11/2014 11:24

- Hikma Pharmaceuticals reports a strong performance in its Injectables, Branded and Generics businesses and has raised its guidance for 2014 group revenue growth of around 7%. The group says its financing position remains very strong and will enable it to make further strategic acquisitions and investments, as opportunities arise. Chairman and chief executive Said Darwazah said: "I am pleased with how our businesses are performing this year. The continued strength of our Injectables business reflects the benefit of our broad portfolio and our success in capturing market opportunities. "The Generics business continues to perform extremely well this year and we are focused on developing our portfolio and pipeline to support future growth. "The Branded business is delivering good growth in a number of important markets and we believe the actions we are taking to restructure our business in Algeria and our commitment to operating in markets impacted by political disruptions, will strengthen our business for the future. " An interim management statement said: "Our global Injectables business is performing well, as we continue to capture specific market opportunities in the US. Competition is increasing in the US and we expect underlying sales in the second half to be broadly in line with the first half of the year. In MENA, we are seeing a good performance and are on track to deliver slight growth for the full year, while European contract manufacturing sales remain lower this year. Due to the continued strength of specific market opportunities, we are raising our guidance to around 25% revenue growth in 2014, with an adjusted operating margin of above 35%. "Following our acquisition of Bedford Laboratories in July, we also completed the acquisition of the Ben Venue manufacturing site in Bedford, Ohio in September. This will significantly enhance our R&D capabilities and enable us to expand future capacity for injectables manufacturing. "As previously announced, in October 2014 we received a warning letter from the US Food and Drug Administration ("FDA") related to the inspection of our manufacturing facility in Portugal in March 2014. We will work with the FDA to fully resolve all outstanding issues as quickly as possible. "Revenue in our Branded business is broadly in line with last year. We are delivering good growth in markets such as Egypt and the Gulf Cooperation Council ("GCC") countries, including Saudi Arabia, driven by our strategic focus on newer, higher value products. However, this is being offset by the ongoing restructuring of our business in Algeria and political disruptions, primarily in Iraq and Libya. Overall, we continue to expect the Branded business to deliver low single digit revenue growth for the full year, with an adjusted operating margin of around 21%. "The Generics business continues to perform very strongly this year, reflecting specific market opportunities and the re-introduction of products. We now expect the Generics business to deliver revenue of around $215 million in 2014, with an adjusted operating margin of around 55%. "On 30 September 2014, we received an approval for a New Drug Application for colchicine 0.6mg capsules by the US FDA, under Section 505(b)(2) of the US Federal Food Drug and Cosmetic Act. On 9 October, the US District Court for the District of Delaware granted Takeda Pharmaceuticals U.S.A., Inc. ("Takeda") a temporary restraining order while the court considered a motion by Takeda for a preliminary injunction. On 5 November, the court denied Takeda's motion but extended the temporary restraining order pending appeal. Our guidance for 2014 does not reflect any contribution from colchicine -

[broadwood] 06/11/2014 07:44

Hikma Pharmaceuticals raises revenue guidance

[r ball] 06/11/2014 07:35

price rise yesterday due to results anticipation or court ruling?

[broadwood] 05/11/2014 17:00

IMS tomorrow.

[broadwood] 05/11/2014 14:35

At your peril.

[r ball] 05/11/2014 13:32

a share to ignore.

[r ball] 05/11/2014 13:32

a share to ignore.

[pyemckay] 10/10/2014 11:17

litigation! boo

[pyemckay] 10/10/2014 00:26

HIK. is now approx 97th ranked by market cap in ftse now, It needs to make position 90 to get into ftse 100 which would give it another audience for its shares.

Its only a matter of time now but with markets falling and hikma still advancing it could come sooner than later.

[adamb1978] 03/10/2014 07:18

Sold my shares in HIK. Reason being that I've held for about a year and therefore made 50% but now look at those profits as being at risk given (1) market conditions and (2) the next couple year forecasts for HIK suggesting zero earnings growth (or less) but a >22x PE. The combination of that multiple and growth suggests limited upside to me over the next couple years so better to bank a profit.
All the best for those who continue to hold

[r ball] 01/10/2014 07:57

no reason to sell.

[broadwood] 01/10/2014 06:33

Yep, just seen it.

Hikma Pharmaceuticals has received approval of its new drug application for colchicine 0.6mg capsules by the US Food and Drug Administration. Hikma will market its colchicine under the brand name MITIGARE. MITIGARE is indicated for prophylaxis of gout flares in adults. This NDA has been approved under section 505(b)(2) of the US Federal Food Drug and Cosmetic Act. Hikma chairman and chief executive Said Darwazah said: "This approval demonstrates our strong regulatory capabilities and the successful execution of our strategy to develop a more differentiated product portfolio for the US market

[mirabeau] 30/9/2014 17:16

FDA APPROVAL FOR COLCHICINE

[broadwood] 30/9/2014 16:02

No new broker recs so its a mystery.
Not complaining.

[coppertrader] 30/9/2014 15:00

Someone knows something, nice rise today

[r ball] 30/9/2014 11:21

not any I am aware of.

[broadwood] 30/9/2014 10:37

Going nicely today. Special factors?

[broadwood] 29/9/2014 08:15

HIKMA Pharmaceuticals, which manufactures generic pharmaceutical products, is reportedly looking at buying US-based rival CorePharma for up to $1bn (£615m).